Hansen, Henrik H.
Grønlund, Rikke V.
Baader-Pagler, Tamara
Haebel, Peter
Tammen, Harald
Larsen, Leif Kongskov
Jelsing, Jacob
Vrang, Niels
Klein, Thomas
Article History
Received: 22 February 2021
Accepted: 31 March 2021
First Online: 13 April 2021
Competing interests
: HHH, RVG, and LKL are employed by Gubra; NV and JJ are owners of Gubra; TB-P, PH and TK are employed by Boehringer Ingelheim Pharma; HT is employed by PXBioVisioN. This study was supported by Boehringer Ingelheim Pharma.